In another example, preclinical studies in rodents indicated that restoring the insulin-like growth factor 1 (IGF-1) concentration may prevent or treat BPD by mitigating inflammatory lung injury and stimulating repair (Ley et al., 2013; Hellstrom et al., 2016; Seedorf et al., 2020), prompting the development of SHP607 (Shire Pharmaceuticals), composed of rhIGF-1 and its binding partner rhIGFBP3 (Ley et al., 2013). This evidence concerns the gene IGF1 and bronchopulmonary dysplasia.